<DOC>
	<DOCNO>NCT03076112</DOCNO>
	<brief_summary>The objective study 1 ) compare effect ipragliflozin 50 mg glucose-lowering effect sitagliptin 100 mg patient type 2 diabetes mellitus , whose HbA1c level ≥ 7.5 % sulfonylurea metformin , 2 ) investigate change metabolic cardiovascular risk factor triglyceride , HDL-cholesterol , uric acid , blood pressure , inflammatory marker , 3 ) examine change body composition include fat muscle mass volume status .</brief_summary>
	<brief_title>Efficacy Ipragliflozin Compared With Sitagliptin Uncontrolled Type 2 Diabetes With Sulfonylurea Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes HbA1c 7.5 % 9.0 % screen visit Male female 20 75 year age Patients take sulfonylurea ( glimepiride 1~8mg gliclazide 30~120 mg equivalent dose ) metformin ( ≥ 1000 mg maximum tolerate dose ) 3 month BMI ≥23 kg/m² Estimated GFR ≥ 60 ml/min/1.73m² Women child bear potential must take precaution avoid pregnancy throughout study 4 week intake last dose must negative urinary pregnancy test . Type 1 diabetes , gestational diabetes , diabetes secondary cause Patients acute coronary syndrome within 3 month prior screen visit Patients acute coronary syndrome within 3 month prior screen visit Pregnant breastfeed woman reproductiveage woman refuse contraception Chronic hepatitis B C ( except healthy carrier HBV ) , liver disease ( AST/ALT &gt; 3fold upper limit normal ) Cancer within 5 year ( except squamous cell cancer , cervical cancer , thyroid cancer appropriate treatment ) except thyroid cancer carcinoma situ Other clinical trial within 30 day Alcohol abuse Contraindication SGLT2 inhibitor Dipeptidylpeptidase 4 inhibitor Taking insulin , oral hypoglycemic agent metformin , sulfonylurea , study drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ipragliflozin</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>